Cytogenetic observations after meglumine antimoniate therapy for visceral leishmaniasis.

@article{Hantson1996CytogeneticOA,
  title={Cytogenetic observations after meglumine antimoniate therapy for visceral leishmaniasis.},
  author={Philippe Hantson and Elizabeth Dermody Leonard and M C Crutzen-Fayt and Allison Leonard and Bernard C Vandercam and B{\'e}n{\'e}dicte Delaere and Paul Mahieu},
  journal={Pharmacotherapy},
  year={1996},
  volume={16 5},
  pages={
          869-71
        }
}
Few data are available concerning the genotoxic effects of antimonial salts therapy in humans. A patient suffering from visceral leishmaniasis was treated for 15 days with a cumulative dose meglumine antimoniate 42.5 g. Peripheral blood lymphocytes sampled before treatment, 7 days later, and at the end of therapy (day 15) were examined for the presence of structural chromosome aberrations, sister chromatid exchanges (SCEs), and micronuclei in binucleated cells. The treatment resulted in an… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.